CFGS
BMRN icon

Concourse Financial Group Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

Concourse Financial Group Securities’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15
Closed -$930 – 241
2024
Q4 		$930 Hold
15
– – ﹤0.01% 2107
2024
Q3 		$1.05K Sell
15
-36
-71% -$3.01K ﹤0.01% 2061
2024
Q2 		$4.2K Sell
51
-4,437
-99% -$369K ﹤0.01% 1899
2024
Q1 		$392K Buy
4,488
+251
+6% +$22.5K 0.03% 493
2023
Q4 		$409K Sell
4,237
-235
-5% -$20.8K 0.03% 486
2023
Q3 		$396K Buy
4,472
+292
+7% +$26K 0.03% 458
2023
Q2 		$362K Buy
4,180
+454
+12% +$42.7K 0.03% 494
2023
Q1 		$362K Buy
3,726
+1,112
+43% +$115K 0.03% 497
2022
Q4 		$271K Sell
2,614
-400
-13% -$37.6K 0.02% 543
2022
Q3 		$255K Sell
3,014
-141
-4% -$12.6K 0.02% 489
2022
Q2 		$261K Sell
3,155
-1,966
-38% -$157K 0.02% 538
2022
Q1 		$395K Sell
5,121
-5,274
-51% -$441K 0.03% 476
2021
Q4 		$918K Buy
10,395
+308
+3% +$25.4K 0.05% 348
2021
Q3 		$780K Buy
10,087
+1,286
+15% +$101K 0.05% 377
2021
Q2 		$734K Buy
8,801
+1,512
+21% +$120K 0.05% 373
2021
Q1 		$550K Buy
7,289
+4,787
+191% +$391K 0.04% 409
2020
Q4 		$219K Buy
2,502
+1,408
+129% +$112K 0.02% 604
2020
Q3 		$83K Buy
1,094
+987
+922% +$99.9K 0.01% 852
2020
Q2 		$13K Buy
107
+20
+23% +$1.99K ﹤0.01% 1419
2020
Q1 		$7K Buy
87
+9
+12% +$775 ﹤0.01% 1541
2019
Q4 		$7K Buy
78
+49
+169% +$3.7K ﹤0.01% 1523
2019
Q3 		$2K Sell
29
-537
-95% -$41.4K ﹤0.01% 1511
2019
Q2 		$48K Buy
566
+387
+216% +$33.1K ﹤0.01% 877
2019
Q1 		$15K Buy
179
+69
+63% +$6.39K ﹤0.01% 1360
2018
Q4 		$9K Sell
110
-51
-32% -$4.85K ﹤0.01% 1447
2018
Q3 		$16K Buy
+161
New +$16.1K ﹤0.01% 926

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Concourse Financial Group Securities's BMRN Position: Q1 2025 in Review

Concourse Financial Group Securities sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 15 shares — an estimated $930 sold.

Concourse Financial Group Securities first reported a position in BMRN in Q3 2018 and held it in 26 quarters. The position peaked at $918K in Q4 2021. 585 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

  • Concourse Financial Group Securities reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Concourse Financial Group Securities sold 15 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $930.
  • Concourse Financial Group Securities first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 26 quarters.
  • Concourse Financial Group Securities's BioMarin Pharmaceuticals position peaked at $918K in Q4 2021.
  • 585 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Concourse Financial Group Securities's 13F filing for Q1 2025.